NRx Pharmaceuticals (NRXP) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
23 Mar, 2026Opening remarks and agenda
Meeting opened with logistical instructions for participation and Q&A procedures.
Chairman called the meeting to order, thanked participants, and expressed intent for future in-person meetings.
Order of business and rules of conduct were presented to attendees.
Board and executive committee updates
Proposal to elect Chaim Hurvitz and Michael Taylor as Class one directors for a three-year term was introduced.
Shareholder proposals
Proposal to amend the 2021 Omnibus Incentive Plan was presented.
Proposal to ratify Weinberg & Company as independent auditors for 2025 was discussed, with rationale for auditor change explained.
Proposal for a non-binding advisory vote on executive compensation was introduced.
Partial view of Summaries dataset, powered by Quartr API
Latest events from NRx Pharmaceuticals
- FDA review nearly complete; five million units prepared to address U.S. ketamine shortage.NRXP
Status update - Improved losses, $2.2M revenue, $22.3M raised, and major clinical and regulatory milestones.NRXPQ2 2026
- Net loss fell to $1.4M as clinical revenue began and regulatory, clinic, and asset advances accelerated.NRXPQ1 2026
- Reduced losses, cash stable, and drug pipeline advanced with new clinic revenue in 2025.NRXPQ4 2025
- Annual meeting to vote on directors, incentive plan, auditor, and executive compensation.NRXPProxy Filing
- Board recommends approval of director elections, equity plan amendment, auditor, and say-on-pay.NRXPProxy Filing
- Proxy covers director elections, equity plan changes, auditor ratification, and executive pay vote.NRXPProxy Filing
- Advanced drug filings, expanded clinics, improved finances, but funding risks persist.NRXPQ1 2025
- Losses narrowed, NDA filings advanced, and clinic network expansion underway.NRXPQ4 2024